ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.4370T>G (p.Leu1457Ter)

dbSNP: rs373226793
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000131174 SCV000186120 pathogenic Hereditary cancer-predisposing syndrome 2022-10-18 criteria provided, single submitter clinical testing The p.L1457* pathogenic mutation (also known as c.4370T>G), located in coding exon 28 of the ATM gene, results from a T to G substitution at nucleotide position 4370. This changes the amino acid from a leucine to a stop codon within coding exon 28. This mutation was identified in 1/102 high risk patients with prostate cancer (Pilié PG et al. Cancer, 2017 Oct;123:3925-3932). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Counsyl RCV000411522 SCV000487090 likely pathogenic Ataxia-telangiectasia syndrome 2016-10-05 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000411522 SCV001199386 pathogenic Ataxia-telangiectasia syndrome 2023-11-28 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Leu1457*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with prostate cancer (PMID: 28657667). ClinVar contains an entry for this variant (Variation ID: 142188). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV001560591 SCV001783031 pathogenic not provided 2023-03-20 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 24763289, 23807571, 25614872, 28657667)
Baylor Genetics RCV003467163 SCV004210192 pathogenic Familial cancer of breast 2023-07-07 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003467163 SCV004932325 pathogenic Familial cancer of breast 2024-01-24 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV003467163 SCV005397947 pathogenic Familial cancer of breast 2024-11-18 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.